Cobenfy in Alzheimer’s: is consensus too dismissive?

Ahead of the 2H26 Alzheimer’s ADEPT-2 Cobenfy phase III readout, our new report focuses on a simple question: is the market framing the programme too conservatively relative to its clinical and commercial potential? With the psychosis readout approaching and broader Alzheimer’s expansion opportunities still treated by many investors as low probability, we think Cobenfy remains an underappreciated re-rating opportunity, with the existing clinical evidence suggesting more upside than current expectations imply.

We address a number of key investor questions:

• Has the original xanomeline liability been mitigated sufficiently to reopen the Alzheimer’s opportunity?

• Why might Alzheimer’s symptoms be addressable through a mechanism distinct from standard antipsychotics?

• What role does KarX-EC play in the cognition and agitation programmes?

• How should investors think about Cobenfy’s fit versus current symptomatic approaches in Alzheimer’s?

• What is the realistic market size under conservative assumptions?